- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04215198
NEM® + KD PUR® Fish Oil Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women (Move3)
Efficacy of the NEM® Brand Eggshell Membrane + KD PUR® Brand Fish Oil Combination (Move3™) Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Springfield, Missouri, United States, 65802
- QPS Bio-Kinetic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female subjects must be 40-75 years of age at the time of Screening.
- Subjects must not have been diagnosed with a JCT disease (i.e. osteoarthritis, rheumatoid arthritis, spondyloarthritis, bursitis, gout, systemic lupus erythematosus, fibromyalgia, etc.) affecting the hip, knee, or ankle by a licensed physician prior to enrollment evaluation / screening.
- Subjects must have a resting pain/discomfort score of ≤ 2 on the 10-point continuous scale in the knee with the most severe pain/discomfort at the Follow-Up Screening/Baseline (first exercise visit).
- Subjects must be willing and healthy enough, as judged by the clinical Investigator or Sub-Investigator(s), to perform moderate exercise.
- Subjects must be available for and willing to attend all evaluation visits.
- Subjects must be able and willing to give informed consent.
- Subjects must be willing to use only acetaminophen as rescue pain medication, if needed.
- Subjects participating in prior studies evaluating eggshell membrane, curcumin, fish oil or collagen can participate in the present study so long as they are not currently taking an eggshell membrane, fish oil, curcumin, or collagen supplement and have not done so for 60 days prior to screening.
Exclusion Criteria:
- Subject is currently receiving therapy with remission-inducing drugs (i.e. methotrexate, TNF biologics, etc.), immunosuppressive drugs (i.e. corticosteroids, transplantation medications, etc.) or planning to use these products during the study period.
- Subject has been diagnosed with any clinically significant confounding inflammatory disease or condition that would interfere with the study evaluation, as judged by the clinical investigator (i.e. pseudo gout, Paget's disease, chronic pain syndrome, active rheumatic fever, etc.).
- Subject has known allergy to any of the investigational products, including but not limited to eggs or egg products, fish or fish products, corn or corn oil, and rice or rice flour. If any subject becomes sensitive during the study, they will immediately be excluded from continuing in the study.
- Subject suffers from clinically significant cardiac, pulmonary, or other complications that would prevent them from performing moderate exercise or could pose a risk to the subject's health, as judged by the clinical investigator.
- Subject participates in activities involving intensive use of the lower extremities (i.e. running / jogging, sports, bicycling, dancing, etc.) 2 or more days per week or participates in activities that involve moderate use of the lower extremities (i.e. walking, golfing, yoga, etc.) 3 or more days per week.
- Subject's body weight is greater than 300 pounds (136.1 kg) at the time of Screening.
Subject is currently taking or is unwilling to forgo the use of prescription, over-the-counter (OTC) treatments, and/or dietary supplements affecting joint health within 30 days prior to baseline evaluation and for the duration of the study. Prohibited medications include: NSAIDs, analgesics (other than acetaminophen), opioids, anti-depressants (of all drug classes for this indication, including but not limited to SSRI's such as citalopram and fluoxetine, TCA's such as amitriptyline and amoxapine, SNRI's such as duloxetine or SNRI's used for fibromyalgia such as milnacipran and NDRI's such as bupropion), other medications for the management of painful conditions (i.e. fibromyalgia) including gabapentin and tizanidine & joint supplements. Examples of these types of medications are: aspirin, ibuprofen, naproxen, oxycodone, propoxyphene, diclofenac, celecoxib, amitriptyline, duloxetine, glucosamine, chondroitin, MSM, white willow bark, turmeric or curcumin, Boswellia, fish oil, etc.
a. Washout Periods: Subjects are eligible to participate in the study following a 7-day washout period for opioids, a 14-day washout period for analgesics & NSAIDs, and a 90-day washout period for steroids, anti-depressants, or JCT dietary supplements (i.e. glucosamine, chondroitin, MSM, etc.) Acetaminophen must not have been taken within 24 hours of the first baseline evaluation.
- Subject is involved in any other research study involving an investigational product (drug, device or biologic) or a new application of an approved product, within 30 days of the first baseline evaluation.
- Pregnant and breastfeeding women, or women who intend to become pregnant during the course of the study.
- Subject has a history or positive test result of HIV, hepatitis B or hepatitis C.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Move3™ (NEM + fish oil)
NEM, 500 mg, #0 capsule, + fish oil, 1,500 mg, softgels, once daily orally for 2 weeks
|
Dietary supplement combination for the support of joint health.
|
Placebo Comparator: Placebo
Placebo, 500 mg, #0 capsule, + placebo oil, 1,500 mg, softgels, once daily orally for 2 weeks
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise-induced Cartilage Turnover via CTX-II Biomarker
Time Frame: 2 weeks
|
To evaluate the efficacy of Move3™ versus placebo at reducing exercise-induced cartilage turnover in healthy men & women by evaluating the change in urinary CTX-II levels.
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exercise-induced Joint Pain via questionnaire
Time Frame: 2 weeks
|
To evaluate the efficacy of Move3™ versus placebo at reducing exercise-induced knee discomfort (pain/aching) based upon perceived pain rated on a 0-10 point continuous scale (where 0 = no pain).
|
2 weeks
|
Exercise-induced Joint Stiffness via questionnaire
Time Frame: 2 weeks
|
To evaluate the efficacy of Move3™ versus placebo at reducing exercise-induced knee stiffness based upon perceived stiffness rated on a 0-10 point continuous scale (where 0 = no stiffness).
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kevin Ruff, Ph.D., ESM Technologies, LLC
- Principal Investigator: Kayce Morton, D.O., QPS Bio-Kinetic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ESM-CLN#2018T02b
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise-induced Joint Pain
-
ESM Technologies, LLCQPS Bio-KineticCompletedExercise-induced Joint Pain | Exercise-induced Joint Stiffness | Exercise-induced Joint Cartilage TurnoverUnited States
-
ESM Technologies, LLCQPS Bio-KineticCompletedExercise-induced Joint Pain | Exercise-induced Joint Stiffness | Exercise-induced Joint Cartilage TurnoverUnited States
-
ESM Technologies, LLCCompletedExercise-induced Joint Pain Stiffness and Cartilage Turnover
-
Ankara Yildirim Beyazıt UniversityCompletedExercise | Patellofemoral Pain Syndrome | Strength | KinesiotapeTurkey
-
Taksim Egitim ve Arastirma HastanesiCompleted
-
Appalachian State UniversityDole Food CompanyCompletedExercise-induced Inflammation | Exercise-induced Oxidative Stress | Exercise-induced Immune DysfunctionUnited States
-
Norwegian University of Science and TechnologyKlinikk for allergi og luftveissykdommerCompletedExercise Induced BronchoconstrictionNorway
-
University of SaskatchewanRecruiting
-
St Mary's University CollegeNot yet recruitingExercise Induced Muscle Damage
-
Universidad Autonoma de Ciudad JuarezCompletedExercise-induced Oxidative Stress
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States